FGFR3 Y647C

CI-VAR-00004835Explore in graph →NP_000133.1:p.Tyr647CysNM_000142.5:c.1940A>GCIViC 3514

Curated evidence

Evidence by cancer (3 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–3 of 3 evidence items across 2 cancer contexts on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Malignant Neoplasm1
FGFR3 Y647C	(oncogenic)	Oncogenic	D	Does Not Support Oncogenicity	2	submitted	EID13202 In a saturation mutagenesis study, all possible point mutations in the FGFR 1-4 kinase domain (amino acids 472-807 for FGFR3) were tested. Lentiviral plasmids were infected at MOI < 0.3 into the growt… (full text at CIViC) PMID 41361008 · Tangermann et al., 2025 · Open in CIViC	civic
Unmapped disease2unmapped disease
FGFR3 Y647C	(functional)	Functional	D	Does Not Support Gain Of Function	2	rejected	EID9705 Variant reported within a comprehensive study of FGFRs intracellular variants (highlight in the KD) and insight in FGFR-selective tyrosine kinase inhibitors. Y647C was related to lung cancer, observed… (full text at CIViC) PMID 26992226 ·

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.